Related Experiment Video
Updated: Jul 18, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Abiraterone-Induced Hypokalemia: A Case Report
Bernard I Nkwocha1, Meenu Singh1
1Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, USA.
Abiraterone prescriptions are rising for prostate cancer. This case report details abiraterone-induced hypokalemia, emphasizing close electrolyte monitoring for improved patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Endocrinology
Background:
- Abiraterone acetate is an FDA-approved androgen biosynthesis inhibitor for metastatic castration-resistant prostate cancer.
- Prescription rates for abiraterone have increased due to an aging population and prostate cancer's association with age.
- Awareness of abiraterone's adverse effects is crucial for optimizing patient care.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Antihypertensive Drugs: Potassium-Sparing Diuretics
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease III: Interprofessional Care